Innovative biotech TheraLase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) received more good news on its lead cancer treating compound TLD-1433 ahead of a human clinical trial.
The candidate is a light activated photo dynamic compound (PDCs) to destroy cancer and has been shown to be able to stay stable over 18 months
“Demonstrating long term stability of a drug to be used in human clinical testing is essential to prove that the potency and/or efficacy of the drug is not affected during prolonged shelf life,” the biotech group said in a regulatory statement.
“TLD-1433, in the most recent testing report, demonstrated that its purity has changed less than 0.34% in 18 months of long term stability testing, indicating extreme stability of the compound.”
Six months of accelerated stability and 18 months long term stability testing have now been successfully completed, the firm said, and the next long term stability reporting period will be at 24 months.
TLD-1433 has demonstrated that it has remained stable at these reported time periods and according to Health Canada guidelines, accelerated and long term stability has now been proven at 6 months and 18 months, respectively, allowing use in treating patients in a clinical study.
Theralase said it was currently focused on enrolling patients in a Phase Ib clinical trial for patients afflicted with Non-Muscle Invasive Bladder Cancer (NMIBC) with anti-cancer drug TLD-1433.
It will assess the primary endpoints of safety and tolerability, with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.
Shares in Toronto added 5.66% to C$0.28 each in early deals.
Story by ProactiveInvestors